Last updated: August 7, 2026
REDITREX is a branded, preservative-free methotrexate injection marketed by Cumberland Pharmaceuticals for subcutaneous treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and severe psoriasis. The product competes in a mature, price-sensitive market against generic methotrexate injections, oral methotrexate, and other prefilled methotrexate products.
Its commercial opportunity depends more on delivery convenience, adherence, payer coverage, and physician preference than on molecule-level differentiation. Cumberland does not separately disclose REDITREX revenue in its public filings, so product-specific sales, margins, and growth rates cannot be calculated from reported financial statements. The company reports product revenue at an aggregated level. (Cumberland Pharmaceuticals, 2024)
What is REDITREX and how does it work?
REDITREX contains methotrexate, an antimetabolite and immunosuppressive drug. It is supplied as a single-dose, preservative-free solution for subcutaneous injection in prefilled syringes.
REDITREX indications and dosage forms
The FDA-approved indications are:
- Rheumatoid arthritis in adults
- Polyarticular juvenile idiopathic arthritis in children
- Severe, recalcitrant, disabling psoriasis in adults
REDITREX is administered once weekly. The product is available in multiple fixed-dose prefilled syringes, allowing patients to self-administer without drawing medication from a vial. The delivery system targets patients who need injectable methotrexate but prefer a prefilled format over a vial and syringe.
The product is not approved for intravenous, intramuscular, or intrathecal use. The prescribing information includes boxed warnings and contraindications relating to pregnancy, hepatotoxicity, myelosuppression, serious infections, pulmonary toxicity, renal impairment, and dosing errors. (U.S. Food and Drug Administration, 2019)
When was REDITREX approved and launched?
The FDA approved REDITREX on July 10, 2019, under New Drug Application No. 211976. Cumberland Pharmaceuticals commercialized the product in the United States after approval. (U.S. Food and Drug Administration, 2019)
REDITREX regulatory timeline
| Event |
Date |
Relevance |
| FDA approval |
July 10, 2019 |
Established REDITREX as an approved methotrexate injection product |
| Commercial launch |
2019 |
Initiated branded competition in prefilled methotrexate |
| Three-year new-drug exclusivity window |
Approximately July 2022 |
Any applicable dosage-form exclusivity would have expired by this point |
| Current status |
Marketed |
No biologic exclusivity framework applies |
REDITREX was approved as a new formulation and delivery presentation of an old active ingredient. Methotrexate has been used clinically for decades, and the product does not benefit from new-molecule exclusivity.
What patents protect REDITREX?
REDITREX has limited molecule-level patent protection because methotrexate is an established generic active pharmaceutical ingredient. The principal commercial protection comes from the product’s formulation, presentation, device configuration, trademarks, regulatory approval, and manufacturing know-how.
REDITREX Orange Book status
The FDA Orange Book is the central source for patents and exclusivity associated with approved drugs. REDITREX’s commercial position does not appear to depend on a long-dated Orange Book patent estate comparable to newer specialty medicines. The active ingredient itself is not protected by an enforceable composition-of-matter patent.
The relevant protection categories are:
| Protection category |
REDITREX position |
| New chemical entity exclusivity |
Not applicable |
| Composition-of-matter patent |
Not applicable for methotrexate |
| Method-of-use patents |
Limited commercial relevance because methotrexate uses are longstanding |
| Formulation patents |
Potentially relevant, but not a visible long-duration barrier to generic methotrexate |
| Device or syringe claims |
Could support enforcement against copying of a specific presentation |
| Trademark protection |
Protects the REDITREX brand, not methotrexate itself |
| Regulatory exclusivity |
Any three-year product-specific exclusivity has expired |
The practical result is a low patent barrier to competing methotrexate products. A competitor does not need to duplicate the REDITREX device to enter the broader methotrexate market.
When does REDITREX lose exclusivity?
REDITREX does not have a conventional patent cliff comparable to a patented small-molecule medicine. Its market exclusivity was structurally limited from launch because methotrexate was already available as a generic drug and multiple injectable presentations existed.
The likely loss of meaningful regulatory exclusivity occurred around 2022, assuming the standard three-year exclusivity period applied to the approved dosage form. Even before that date, generic methotrexate products could compete in adjacent dosage forms and administration formats.
REDITREX generic-entry risk
The main entry risks are:
- Generic injectable methotrexate in vials or other presentations.
- Competing prefilled methotrexate syringes.
- Lower-cost oral methotrexate.
- Payer-directed substitution.
- Biosimilar-like competitive pressure from other injectable immunosuppressive therapies, although no biosimilar approval pathway applies directly to REDITREX.
A generic applicant seeking to market an equivalent product could use an abbreviated approval pathway if it meets applicable FDA requirements. A Paragraph IV challenge is possible only where an applicant identifies a listed patent as invalid, unenforceable, or not infringed. Because REDITREX does not appear to rely on a substantial long-duration Orange Book patent estate, Paragraph IV litigation is less likely to be the primary competitive threat than ordinary generic substitution and reimbursement pressure.
How large is the REDITREX market?
The addressable market is broad but fragmented. Methotrexate is used across rheumatology, dermatology, and pediatric rheumatology. Most prescriptions remain exposed to generic substitution.
Market segmentation
| Segment |
REDITREX opportunity |
Competitive pressure |
| Rheumatoid arthritis |
Largest potential segment |
High; oral and injectable generic methotrexate dominate |
| Polyarticular juvenile idiopathic arthritis |
Smaller, specialist-driven segment |
Moderate; adherence and administration convenience matter |
| Severe psoriasis |
Established use but reduced by biologics |
High from biologics and oral alternatives |
| Self-administered injectable therapy |
Core commercial niche |
Competes with Rasuvo, Otrexup, and generic injection options |
| Oral methotrexate |
Substitute rather than direct equivalent |
Strong payer and physician preference for low-cost tablets |
The market has a relatively low cost of goods for the active ingredient, while the branded product carries value through prefilled delivery, dose convenience, and patient usability. That value is difficult to preserve when payers treat the product as therapeutically interchangeable with generic methotrexate.
How does REDITREX compare with Rasuvo and Otrexup?
REDITREX competes most directly with other subcutaneous, prefilled methotrexate products.
| Product |
Active ingredient |
Delivery |
Sponsor or marketer |
Competitive position |
| REDITREX |
Methotrexate |
Prefilled subcutaneous syringe |
Cumberland Pharmaceuticals |
Branded convenience product |
| Rasuvo |
Methotrexate |
Prefilled subcutaneous autoinjector |
Medac Pharma |
Established specialty product |
| Otrexup |
Methotrexate |
Single-dose subcutaneous autoinjector |
Antares Pharma legacy product |
Device-led alternative |
| Generic methotrexate |
Methotrexate |
Vial, syringe, or other injectable formats |
Multiple manufacturers |
Lowest-cost substitute |
| Oral methotrexate |
Methotrexate |
Tablets or oral solution |
Multiple manufacturers |
Dominant low-cost alternative |
REDITREX versus Rasuvo
Rasuvo has an earlier market presence and strong recognition among prescribers seeking an autoinjector. REDITREX competes through a prefilled syringe format and Cumberland’s specialty pharmaceutical distribution infrastructure. The products address similar clinical needs, but device usability, formulary placement, copay support, and pharmacy access can determine product selection.
REDITREX versus Otrexup
Otrexup also targets self-administered subcutaneous methotrexate. Its market position has been affected by commercial ownership changes and the broader difficulty of sustaining premium pricing for an established generic molecule. REDITREX faces the same structural challenge: a device-based value proposition must offset a substantial price gap versus generic methotrexate.
What is the FDA regulatory status of REDITREX?
REDITREX remains an FDA-approved prescription product. Its approval covers the listed rheumatology and psoriasis indications and the approved subcutaneous dosage forms.
The FDA label includes standard methotrexate risk controls, including:
- Weekly rather than daily administration
- Laboratory monitoring
- Dose adjustments in renal impairment
- Pregnancy restrictions
- Liver toxicity monitoring
- Bone-marrow suppression warnings
- Infection and pulmonary toxicity warnings
- Avoidance of certain interacting drugs and vaccines
These safety requirements can increase the value of a ready-to-use product because a prefilled syringe reduces preparation steps and may reduce some administration errors. They do not, however, eliminate the need for clinician monitoring or reduce the underlying toxicity risk of methotrexate.
What is the financial trajectory of REDITREX?
Public financial disclosure limits product-level analysis. Cumberland Pharmaceuticals reports consolidated revenue and does not provide a complete, recurring REDITREX revenue series in its annual filings. As a result, the following conclusions are more reliable than an unsupported product revenue estimate:
- REDITREX is a commercial product within Cumberland’s branded portfolio.
- The company does not disclose product-specific revenue, gross margin, prescription volume, or market share sufficient to calculate REDITREX growth independently.
- REDITREX revenue is exposed to payer rebates, specialty pharmacy economics, gross-to-net adjustments, and generic competition.
- Product profitability is likely more sensitive to net pricing and sales infrastructure than to active pharmaceutical ingredient costs.
- A larger share of revenue from REDITREX would improve portfolio diversification but could increase exposure to a single mature therapeutic category.
Financial drivers
Net pricing
The largest financial risk is erosion of net price. REDITREX competes against a low-cost generic molecule, so formulary managers can demand rebates or restrict access unless the product demonstrates measurable adherence or administration benefits.
Prescription mix
Patients who cannot tolerate oral methotrexate, have inadequate control on oral therapy, or need a reliable home-injection format are more commercially attractive than the broad methotrexate population. The premium injectable segment is narrower than total methotrexate demand.
Patient support
Copay assistance, nurse education, injection training, and specialty pharmacy services can increase initiation and persistence. Those programs also reduce contribution margin if they require substantial manufacturer funding.
Specialty channel exposure
Distribution through specialty pharmacies can improve patient service and monitoring but may increase administrative complexity, rebate exposure, and working-capital requirements.
Portfolio economics
Cumberland’s financial performance depends on its broader portfolio, including hospital and outpatient products. REDITREX should therefore be assessed as one contributor to the company’s revenue mix rather than as a separately valued public company asset. (Cumberland Pharmaceuticals, 2024)
What manufacturing and intellectual-property barriers affect REDITREX?
Manufacturing barriers are moderate rather than prohibitive.
Manufacturing considerations
A competing product must solve several technical issues:
- Methotrexate stability in the selected container
- Compatibility with the prefilled syringe and needle system
- Accurate delivery across multiple fixed doses
- Sterility assurance
- Extractables and leachables control
- Packaging and light-protection requirements
- Container-closure integrity
- Compliance with injectable product manufacturing standards
These requirements can delay entry, but they do not create the same barrier as a complex biologic manufacturing process. Methotrexate is a relatively well-characterized small molecule with established manufacturing routes and extensive prior regulatory history.
IP considerations
The strongest potential IP position would involve:
- A specific methotrexate concentration or excipient system
- A syringe or administration device configuration
- A method for improving stability
- A packaging system
- A dosing or administration method
Such rights would generally protect a narrow product configuration. They would not block generic methotrexate tablets, vials, or alternative prefilled devices unless the competitor practiced the specific protected claims.
Which companies are challenging REDITREX commercially?
The main competitive challenge comes from product categories rather than a single litigation opponent.
Direct competitors
- Medac Pharma through Rasuvo
- Antares Pharma’s legacy Otrexup platform
- Generic injectable methotrexate manufacturers
- Generic oral methotrexate manufacturers
Therapeutic competitors
In rheumatoid arthritis and psoriasis, biologic and targeted synthetic therapies compete with methotrexate as treatment alternatives or add-on therapies. These include tumor necrosis factor inhibitors, interleukin inhibitors, Janus kinase inhibitors, and other disease-modifying antirheumatic drugs.
Biologics generally have higher prices but stronger clinical differentiation. They can reduce methotrexate use in some patients, particularly those with inadequate response or intolerance. REDITREX can also remain part of combination therapy, so biologic growth does not eliminate its addressable market.
What litigation and settlement risks affect REDITREX?
There is no widely reported, high-value patent litigation campaign comparable to the litigation surrounding heavily patented specialty medicines. The principal legal risks are more likely to involve:
- Product liability
- Labeling and medication-error claims
- Manufacturing or quality disputes
- Patent disputes over a specific device or formulation
- Contract and distribution disputes
- Reimbursement and promotional compliance
A Paragraph IV settlement would have limited strategic value unless a competitor sought to copy a protected REDITREX presentation. The absence of a material composition patent reduces the likelihood of a settlement that controls the entire methotrexate market.
What generic launch scenarios exist for REDITREX?
Scenario 1: Gradual branded erosion
Generic methotrexate remains available, but some specialists continue prescribing REDITREX for patients who value the prefilled format. Revenue declines gradually as payers expand preferred generic coverage.
Scenario 2: Direct prefilled-syringe generic
A generic or authorized alternative copies the practical delivery format. This scenario would create the greatest pressure on REDITREX because it would remove the principal product differentiator while preserving therapeutic equivalence.
Scenario 3: Formulary exclusion
A major payer excludes REDITREX or places it behind generic methotrexate. New-patient starts fall rapidly, and Cumberland must rely on existing patients, appeals, and patient-support programs.
Scenario 4: Stable specialty niche
REDITREX retains a focused position in patients who need injectable therapy and benefit from a ready-to-use syringe. Revenue remains stable but growth is limited because the total premium injectable market is narrow.
How strong is the REDITREX commercial position?
REDITREX has moderate product utility but weak structural exclusivity.
| Factor |
Assessment |
| Clinical differentiation |
Low |
| Administration convenience |
Moderate |
| Patent durability |
Low |
| Regulatory complexity |
Moderate |
| Generic substitution risk |
High |
| Biosimilar risk |
Not applicable |
| Payer sensitivity |
High |
| Manufacturing complexity |
Moderate |
| Long-term pricing power |
Low to moderate |
| Specialty-market durability |
Moderate |
The product’s best defense is a focused patient segment that values injectable convenience and predictable dosing. Its weakest point is the availability of low-cost methotrexate across multiple dosage forms.
Key Takeaways
- REDITREX is a branded, prefilled subcutaneous methotrexate product approved by the FDA in 2019.
- Cumberland Pharmaceuticals does not separately disclose REDITREX revenue, preventing a verified product-level financial trajectory.
- The product competes with Rasuvo, Otrexup, generic injectable methotrexate, and oral methotrexate.
- Methotrexate’s established status creates little molecule-level exclusivity.
- Any three-year product-specific regulatory exclusivity would have expired around 2022.
- The primary commercial risks are payer restrictions, net-price erosion, and direct competition from lower-cost prefilled methotrexate.
- Biosimilar risk does not apply because REDITREX is a small-molecule drug, not a biologic.
- REDITREX’s strongest commercial attribute is delivery convenience; its weakest is limited clinical and IP differentiation.
- Long-term value depends on retaining a specialty niche rather than sustaining broad premium pricing.
FAQs About REDITREX Market and Financial Outlook
Is REDITREX a biologic or a generic drug?
REDITREX is a branded drug containing methotrexate. It is not a biologic and does not face biosimilar competition. Generic methotrexate products compete with it directly.
Who manufactures REDITREX?
Cumberland Pharmaceuticals markets REDITREX in the United States. Manufacturing and supply-chain arrangements may involve external pharmaceutical manufacturing partners.
Does REDITREX have an Orange Book patent?
REDITREX does not appear to rely on a long-duration composition patent because methotrexate is an established active ingredient. Any relevant listing would need to be verified against the current FDA Orange Book.
Can patients substitute oral methotrexate for REDITREX?
Oral methotrexate is a potential therapeutic substitute, but it is not automatically interchangeable with a subcutaneous REDITREX prescription. The choice depends on clinical response, tolerability, absorption, adherence, and physician judgment.
What would increase REDITREX sales?
Sales could increase through stronger payer coverage, broader specialist adoption, improved patient-support services, evidence of adherence benefits, and growth in patients requiring injectable methotrexate. Price increases alone are unlikely to provide durable growth in a generic-exposed market.
References
-
Cumberland Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2019). REDITREX (methotrexate) injection, for subcutaneous use: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
